Galangin Protects against Symptoms of Dextran Sodium Sulfate-Induced Acute Colitis by Activating Autophagy and Modulating the Gut Microbiota

Galangin is a natural flavonoid that has been reported to provide substantial health benefits. Nevertheless, little is known about the potential effects of galangin against inflammatory bowel diseases. Here, an in vivo study was performed to investigate the preventive effects of galangin against dextran sulphate sodium (DSS)-induced acute murine colitis, which mimics the symptoms of human ulcerative colitis (UC). Pre-treatment with galangin (15 mg/kg, p.o.) resulted in a significant decreased in the macroscopic signs of DSS-induced colitic symptoms, including a decreased disease activity index, prevention of the colon length shortening, and alleviation of the pathological changes occurring in the colon. Colonic pro-inflammatory mediators, including tumor necrosis factor-alpha, interleukin (IL)-1 beta, and IL-6, as well as myeloperoxidase activities were decreased following galangin pre-treatment when compared with the DSS control group. Moreover, galangin pre-treatment significantly increased the expressions of autophagy-related proteins and promoted the formation of autophagosome in the colon. Galangin pre-treatment increased the diversity of the gut microbiota, and this was accompanied by increased levels of short-chain fatty acids. These observed changes could involve the modulating effects conferred by galangin in relation to some specific bacteria populations, including the recovery of Lactobacillus spp., and increased Butyricimonas spp. Overall, these results support the use of galangin in the prevention of UC.


Introduction
Inflammatory bowel diseases (IBD) consist of two partially overlapping clinical entities, Crohn's disease (CD) and ulcerative colitis (UC), which have demonstrated a rapidly increasing incidence worldwide [1]. CD typically presents as scattered transmural inflammation of the patients' gastrointestinal (GI) tract, whereas mucosal inflammation in patients with UC is limited to the colon [2]. Although the pathogenesis of IBD remains unknown, several therapeutic approaches, which mainly focus on immunosuppression and anti-inflammation, have been developed. However, patients with IBD receiving such treatments often do not achieve full remission and have a high possibility of recurrence. In total,

Animal Experiments
Male ICR mice (7 weeks old, 22-24 g) were purchased from Shanghai Laboratory Animal Research Center (Shanghai, China). This study was conducted in the Animal Experimental Center of the Zhejiang Institute of Traditional Chinese Medicine in Hangzhou, China, following standard experimental protocols in the SPF environment. The experiment was carried out in accordance with the code for the care and use of animals for scientific purposes (ethic approval code: 171003). Mice were acclimatized to standard laboratory conditions at 23 • C, 12 h/12 h light/dark, and 50% humidity for 4 days prior to the experiment. An AIN-93-based standard lab chow (Xietong Biotechnology, Nanjing, China) was applied to the animals, and all of the mice had free access to feed and water throughout the experimental period. The mice were randomly divided into four treatment groups of equal size (n = 6/group). The treatment groups were: (1) normal control, which received tap water and were not treated with DSS; (2) the DSS colitis control, which received 3% DSS in tap water for 1 week; (3) positive control group, in which mice received 5-aminosalicylic acid (50 mg/kg b.w., p.o.); and (4) galangin treatment group, in which mice received galangin (15 mg/kg b.w., p.o.). Galangin and 5-aminosalicylic acid were dissolved in 0.5% gum tragacanth (solubilizing agent), and administered to the mice 1 week prior to the DSS challenge, up to the end of this study. The normal control and DSS colitis control mice also received the same volume of gum tragacanth. The effect of a treatment on an animal's health was blindly analyzed and the disease activity index (DAI) was chosen for evaluating the colitic severity, which included the loss of body weight, stool consistency, rectal bleeding, and the overall condition of the animals [11].

Histologic Analysis
Distal colonic tissues were collected from the mouse and the digesta were removed. These tissues were fixed in 4% paraformaldehyde for hematoxylin and eosin (H&E) staining following standard protocols. Colonic histological tissues were observed under a light microscope with an attached image capture system (Nikon Eclipse Ci, Japan).
Histological damage to the colon were calculated on the basis of colonic inflammation, the severity of colonic epithelial cell infiltration, crypt destruction, and the extent of cell infiltration, with each of the subscore ranging from 0 to 2 (no changes to maximum tissue damage).

Inflammatory Cytokines Assessments
Colonic proteins were extracted using a RIPA cell lysis buffer, and pro-inflammatory cytokines, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, were measured using commercial enzyme-linked immunosorbent assay kits following standard protocols (Cusabio Biotech, Wuhan, China). Colonic myeloperoxidase (MPO) peroxidase activity was measured on the basis of a previously described colorimetric method, with some modifications [15]. In brief, colonic tissues were extracted using PBS (0.1M, pH = 6.5) with 0.5% hexadecyltrimethylammonium bromide. Then, the reaction solution (0.167 mg/mL of o-dianisidine hydrochloride, 0.0005% hydrogen peroxide) was mixed with the tissue homogenate (0.1 mL with 2.9 mL reaction solution) and then reacted for 5 min. The optical values were subsequently recorded at 460 nm (Molecular Devices, Spectramax M5).

Western Blot Analysis
Colonic proteins were obtained using a commercial protein extraction kit (KeyGen Biotech, Co, Ltd., Nanjing, China). Protein concentration was determined using a BCA protein assay kit (Beyotime Biotechnology, Haimeng, China). Subsequently, equal amounts of proteins (40 µg) were mixed with a quarter-volume of the Laemmli's sample buffer and boiled at 95 • C for 5 min. These samples were then separated via 12-15% SDS-PAGE. The gels were then transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, USA), and 5% skim milk was used to block the nonspecific binding sites for 30 min at room temperature. Primary antibodies (as indicated) were incubated with the membranes at room temperature for 1 h, and horseradish peroxidase (HRP)-conjugated secondary antibodies were then applied for another 1 h incubation. The blots were visualized using ECL Western blotting detection reagents (Abcam, Cambridge, MA, USA).

Transmission Electron Microscopy
For the transmission electron microscopy (TEM) analysis, distal colon samples were fixed using glutaraldehyde (2.5%) and 1% osmium tetroxide (1%) in 0.01 M phosphate. The fixed tissues were then embedded in Epon 812 resin overnight and dried with an acetone gradient following the standard procedures provided by the manufacturer (SPI-EM, Division of Structure Probe, Westchester, NY, USA) [16]. The ultrathin sections were then dried using uranium acid and lead citrate, and subsequently observed under a transmission electron microscope (Hitachi, Tokyo, Japan).

Gut Microbiota Analysis
Cecal digesta were collected, and total DNA was extracted using a QIAamp DNA stool MiniKit (Qiagen, Hilden, Germany). PCR reactions targeting the V3-V4 regions of the 16S rDNA genes (primers: 319F, 5 -ACTCCTACGGGAGGCAGCAG-3 ; 806R, 5 -GGACTACHVGGGTWTCTAAT-3 ) were performed using the Premix Ex Taq Hot Start Version (Takara, Dalian, China) on a gradient PCR instrument. The amplicons were then purified using an AxyPrep DNA gel extraction kit (Axygen Bioscience, Union City, USA). The sequencing reactions were subsequently assessed using an Illumina Miseq PE250 platform (Shanghai Majorbio Bio-pharm Biotechnology Co., China). Raw reads were merged using FLASH (v1.2.11) and then analyzed using QIIME (v1.9.0). The sequences were binned into operational taxonomic units (OTUs) on the basis of 97% identity. Taxonomy analyses were performed using the Ramer-Douglas-Peucker (RDP) algorithm of the Greengenes database. Alpha diversity indices, such as Chao1, Shannon, and Simpson diversity indices, were chosen to estimate the species richness using the Mothur program. Principal coordinate analysis (PCoA) was used to represent the relationships between the samples on the basis of calculations of UniFrac metrics. Heat map and the hierarchical clustering tree at the genus level was calculated based on a UniFrac metrics dissimilarity matrix using Vegan 2.0 packages in R (version 3.1.2) software.

Short-Chain Fatty Acid Analysis
Weighed cecal digesta (~100mg) collected from the mice were diluted at 1:3 (w/w) with 1.68 mmol heptanoic acid/L, which served as an internal standard. Cecal acetate, butyrate, propionate, and minor SCFAs were measured using a gas chromatography system on the basis of a previously published method [16].

Statistics Analysis
Data are presented as arithmetic mean ± standard deviations (SD) for each treatment group. Depending on the number of variables, normally distributed datasets were either compared by one-way ANOVA or repeated-measures ANOVA followed by Tukey's post-hoc tests. A p-value less than 0.05 was considered statistically significant. All statistical tests were performed using SPSS version 17.0 (SPSS, Inc., Chicago, IL).

Galangin Ameliorated AC Symptoms Induced by DSS in Mice
As shown in Figure 1B, a dramatic increase in the DAI following DSS administration (3% in tap water) over 1 week was observed, including decreased weight, stool consistency, and overall condition of the animals, suggesting that the DSS treatment resulted in symptoms similar to that of clinical UC. In comparison with the DSS control group, it can be been seen that the DAI values were significantly inhibited following the galangin and the 5-aminosalicylic acid (5-ASA, reference drug) treatments (both p < 0.001), which corroborate their protective effects against DSS-induced colitis. The colon lengths were substantially shortened in the DSS groups, and this was rescued following galangin treatment ( Figure 1C,D). Correspondingly, distal colonic tissues from the DSS-induced colitis group presented with massive crypt disruptions, ulcerations, and severe inflammation, based on the results of H&E staining ( Figure 1E). These pathological changes were alleviated by the administration of galangin or 5-ASA, which further confirmed the decreasing H&E scores from the semi-quantitative scores of the histological parameters ( Figure 1F).
Nutrients 2020, 12, 347 5 of 13 galangin treatment ( Figure 1C,D). Correspondingly, distal colonic tissues from the DSS-induced colitis group presented with massive crypt disruptions, ulcerations, and severe inflammation, based on the results of H&E staining ( Figure 1E). These pathological changes were alleviated by the administration of galangin or 5-ASA, which further confirmed the decreasing H&E scores from the semi-quantitative scores of the histological parameters ( Figure 1F).

Effects of Galangin on Inflammatory Mediators in DSS-Induced Colitic Mice
In comparison with the control group, the levels of TNF-α, IL-1β, and IL-6 in the DSS groups were clearly increased. Importantly, treatment with galangin resulted in a decrease in these pro-inflammatory cytokines when compared with the DSS colitis control (Figure 2A-C). Galangin treatment also significantly reversed the increase in the colonic MPO activity when compared to the DSS-treated mice ( Figure 2D).
Nutrients 2020, 12, 347 6 of 13 treatment also significantly reversed the increase in the colonic MPO activity when compared to the DSS-treated mice ( Figure 2D).

Galangin Administration Activated Cellular Autophagy in DSS-Induced Colitic Mice
The expressions of autophagy-associated proteins in the colons of DSS-induced colitic mice were assessed. As shown in Figure 3A, it was observed that the autophagy marker proteins, including ATG5, ATG7, ATG12, and LC3B, were downregulated in the colitic mice, compared with the control group. Galangin administration promoted colonic cell autophagy by increasing the aforementioned autophagy-associated proteins. In addition, phosphorylated AMPK expression was decreased in the DSS-treated mice, and this response to DSS was largely reversed following galangin administration. According to TEM analyses, significant epithelial barrier losses were observed in the DSS-treated mice, whereas galangin was shown to significantly induce autophagosome formations in the intestinal epithelial cells.

Galangin Administration Activated Cellular Autophagy in DSS-Induced Colitic Mice
The expressions of autophagy-associated proteins in the colons of DSS-induced colitic mice were assessed. As shown in Figure 3A, it was observed that the autophagy marker proteins, including ATG5, ATG7, ATG12, and LC3B, were downregulated in the colitic mice, compared with the control group. Galangin administration promoted colonic cell autophagy by increasing the aforementioned autophagy-associated proteins. In addition, phosphorylated AMPK expression was decreased in the DSS-treated mice, and this response to DSS was largely reversed following galangin administration. According to TEM analyses, significant epithelial barrier losses were observed in the DSS-treated mice, whereas galangin was shown to significantly induce autophagosome formations in the intestinal epithelial cells.

Galangin Administration Modulated the Gut Microbiota in Colitic Mice
To determine if galangin administration was linked to changes in the gut microbial communities, a high-throughput Illumina MiSeq sequencing approach was employed, which covered the V3-V4 regions of the 16S rRNA gene of the bacteria extracted from the cecal digesta of the colitic mice. As shown in Figure 4A, compared with the normal control, mice from the DSS colitic group showed a remarkable decrease in the community diversity (significant decreases in the Shannon indices and increases in the Simpson indices-both were p < 0.001) and an overall loss of community (decreased Chao1 indices, p < 0.001). Galangin treatment was found to effectively reverse the decrease in the bacterial community diversity induced by DSS (p < 0.01 of Shannon indices, and p < 0.001 of Simpson indices); however galangin treatment was not able to increase the community richness. As shown in Figure 4B, the predominant bacterial phylum in the normal control was Firmicutes (57.4%), followed by Bacteroidetes (39.2%). After DSS treatment, Bacteroidetes were

Galangin Administration Modulated the Gut Microbiota in Colitic Mice
To determine if galangin administration was linked to changes in the gut microbial communities, a high-throughput Illumina MiSeq sequencing approach was employed, which covered the V3-V4 regions of the 16S rRNA gene of the bacteria extracted from the cecal digesta of the colitic mice. As shown in Figure 4A, compared with the normal control, mice from the DSS colitic group showed a remarkable decrease in the community diversity (significant decreases in the Shannon indices and increases in the Simpson indices-both were p < 0.001) and an overall loss of community (decreased Chao1 indices, p < 0.001). Galangin treatment was found to effectively reverse the decrease in the bacterial community diversity induced by DSS (p < 0.01 of Shannon indices, and p < 0.001 of Simpson indices); however galangin treatment was not able to increase the community richness. As shown in Figure 4B, the predominant bacterial phylum in the normal control was Firmicutes (57.4%), followed by Bacteroidetes (39.2%). After DSS treatment, Bacteroidetes were increased to 41.2%, and Firmicutes were decreased to 29.3%, representing a significant increase in Proteobacteria. Correspondingly, compared with the normal mice, a decreased ratio of Bacteroidetes to Firmicutes was observed in the DSS group. Moreover, this ratio was increased following the administration of galangin ( Figure 4C). The PCoA method was then used to further depict the distinct microbial compositions among the control, DSS, and galangin groups ( Figure 4D). A heat map was generated to show the most predominant 20 bacteria genera. It was observed that the control mice had a wide range of bacterial genera, including Lactobacillus spp., Alloprevotella spp., Odoribacter spp., and Roseburia spp., among others. However, DSS induction decreased the relative abundance of some probiotic bacteria, including Lactobacillus spp., and increased the abundance of the pathogenic bacteria, such as Escherichia shigella spp. In addition, treatment with galangin was able to recover the loss of Lactobacillus spp., and induce some specific bacterial groups, including Butyricimonas spp. and Mucispirillum spp. (Figure 4E). increased to 41.2%, and Firmicutes were decreased to 29.3%, representing a significant increase in Proteobacteria. Correspondingly, compared with the normal mice, a decreased ratio of Bacteroidetes to Firmicutes was observed in the DSS group. Moreover, this ratio was increased following the administration of galangin ( Figure 4C). The PCoA method was then used to further depict the distinct microbial compositions among the control, DSS, and galangin groups ( Figure 4D). A heat map was generated to show the most predominant 20 bacteria genera. It was observed that the control mice had a wide range of bacterial genera, including Lactobacillus spp., Alloprevotella spp., Odoribacter spp., and Roseburia spp., among others. However, DSS induction decreased the relative abundance of some probiotic bacteria, including Lactobacillus spp., and increased the abundance of the pathogenic bacteria, such as Escherichia shigella spp. In addition, treatment with galangin was able to recover the loss of Lactobacillus spp., and induce some specific bacterial groups, including Butyricimonas spp. and Mucispirillum spp. (Figure 4E).

Effects of Galangin Administration on the SCFA Composition in Colitic Mice
As shown in Figure 5, the concentrations of fecal SCFAs were determined using GC analysis. A significant decrease in the total SCFAs in the DSS-treated mice when compared with the normal control (p < 0.01) was observed. Three major SCFAs, including acetic, propionic, and butyric acid (~90% of total), also presented with a similar decreasing trend. Following galangin treatment, it was apparent that the decrease in the total SCFAs and the three main SCFAs was reversed to some extent compared to the DSS-induced colitic mice, suggesting that galangin intake could help modulate bacterial metabolites in the gut.
Nutrients 2020, 12, 347 9 of 13 As shown in Figure 5, the concentrations of fecal SCFAs were determined using GC analysis. A significant decrease in the total SCFAs in the DSS-treated mice when compared with the normal control (p < 0.01) was observed. Three major SCFAs, including acetic, propionic, and butyric acid (~90% of total), also presented with a similar decreasing trend. Following galangin treatment, it was apparent that the decrease in the total SCFAs and the three main SCFAs was reversed to some extent compared to the DSS-induced colitic mice, suggesting that galangin intake could help modulate bacterial metabolites in the gut. Figure 5. Galangin administration increased gut SFCAs in DSS-induced colitic mice. Feces were collected from mice and SCFAs were analyzed using GC. Results of acetic acid, propionic acid, butyric acid, and total SCFAs are shown as μg/g of feces f.w. (fresh weight). The stars indicate that values were significantly different (* p < 0.05, ** p < 0.01, and *** p < 0.001) compared with DSS control.

Discussion
Although galangin has been shown to have numerous biological activities, which include key active constituents of many herbs and natural products (including bee propolis [17], Alpinia officinarum Hance [18], etc.), studies assessing the gastrointestinal protective effects of galangin are limited. In the present study, we investigated the potential impact of galangin administration against intestinal inflammation using a mouse UC-like model induced by DSS. Galangin administration to these mice was able to prevent the damage induced by intestinal inflammation, as well as limit the clinical colitic symptoms. Moreover, these effects were mediated via the activation of autophagyrelated cell signaling pathways. We further confirmed the modulating effects of galangin on the gut microbiota and SCFA production in relation to the attenuation of intestinal inflammation.
The incidence of UC has grown rapidly over recent years. UC can severely decrease a patient's quality of life and is also a factor influencing the development of colonic cancer [19]. Even though a number of anti-inflammatory/immunosuppressive drugs (e.g., prednisone, azathioprine, and methotrexate) have been developed, patients sometimes do not achieve full remission [20]. In addition, potential side effects, such as steroid dependence, have also been reported to be associated with these therapies [21]. As such, new therapeutic approaches are warranted for the treatment and/or prevention of UC. The UC model used in the current study was induced in mice using DSS

Discussion
Although galangin has been shown to have numerous biological activities, which include key active constituents of many herbs and natural products (including bee propolis [17], Alpinia officinarum Hance [18], etc.), studies assessing the gastrointestinal protective effects of galangin are limited. In the present study, we investigated the potential impact of galangin administration against intestinal inflammation using a mouse UC-like model induced by DSS. Galangin administration to these mice was able to prevent the damage induced by intestinal inflammation, as well as limit the clinical colitic symptoms. Moreover, these effects were mediated via the activation of autophagy-related cell signaling pathways. We further confirmed the modulating effects of galangin on the gut microbiota and SCFA production in relation to the attenuation of intestinal inflammation.
The incidence of UC has grown rapidly over recent years. UC can severely decrease a patient's quality of life and is also a factor influencing the development of colonic cancer [19]. Even though a number of anti-inflammatory/immunosuppressive drugs (e.g., prednisone, azathioprine, and methotrexate) have been developed, patients sometimes do not achieve full remission [20]. In addition, potential side effects, such as steroid dependence, have also been reported to be associated with these therapies [21]. As such, new therapeutic approaches are warranted for the treatment and/or prevention of UC. The UC model used in the current study was induced in mice using DSS over 7 days, which represents one of the best-characterized animal models for IBD for use in pre-clinical studies [22]. Similar to a previously study, we noticed that the DSS treatment caused mucosal barrier losses as well as inflammation in the intestinal epithelial cells, resulting in diarrhea and shortened colons in the mice [23]. Flavonoids, including galangin have good anti-inflammatory activity, and some specific flavonoids, such as pinocembrin [16], naringenin [24], and phloretin [25] have been demonstrated to have good anti-colitis effects. However, other flavonoids, such as luteolin, can aggravate DSS-induced experimental colitis, suggesting that the mechanisms of action associated with flavonoids are quite complex [26]. As expected, it was noticed that the administration of galangin to these mice had beneficial effects towards alleviating the symptoms associated with acute colitis, including a decreasing DAI, increasing colon length, and protection against histopathological changes in the colonic cells. These macroscopic indices indicated that galangin could effectively suppress the clinical features of colitis induced by DSS in mice.
It has been widely accepted that inflammatory cytokines play key roles in the pathogenesis of IBD [27]. The severity, perpetuation, and complications associated with IBD are also directly correlated with the releases of inflammatory cytokines, which originated from the inflammatory cells (epithelial cells, macrophages, and neutrophils) in the colon [28]. Therefore, controlling the productions of inflammatory cytokines has some merits in regard to evaluating the effectiveness of UC or CD therapies. In clinical practice, specific antibodies against some pro-inflammatory cytokines, including adalimumab (for TNF-α neutralization) and tocilizumab (for IL-6 neutralization), have been shown to have some effectiveness for treating UC patients [15]. Using anti-IL-1β antibodies has also been shown to improve DSS-induced colitis in rodents [29]. In this current study, it was found that galangin had significant effects on decreasing three key pro-inflammatory cytokines (i.e., TNF-α, IL-1β, and IL-6) during colitis, which is supported by previous in vivo studies investigating galangin's anti-inflammatory effects in LPS-injected mouse brains [30] and fructose-fed rat livers [31]. The colonic MPO is a hallmark for the neutrophil cell infiltration. One previous study suggested that galangin does not affect the NADPH oxidase activity, but it does strongly inhibit MPO activity in neutrophils [32]. The current study also found that the elevation in MPO activity induced by DSS was inhibited by galangin. Accompanying the histological analysis, this inferred that galangin was able to help prevent inflammatory cell infiltrations.
Autophagy is a physiological process that results in autophagosomal/lysosomal degradation of damaged cellular organelles or cytoplasmic contents [33]. Increasing evidence suggests that autophagy contributes to the homeostasis of the gastrointestinal system, as it is involved in intestinal cell development, tissue repair, and programmed cell death. The autophagy-related (Atg) genes control autophagosome formation through the Atg12-Atg5 and LC3-II (Atg8-II) complexes, and recent studies have noted that knockout of Atg genes in mice caused aggravation of colitis [34]. Therefore, activation of autophagy by dietary flavonoids/polyphenols could have great potential for controlling colitis. For example, one previous study demonstrated that a polyphenolic extract from mango (Mangifera Indica L.) had anti-colitis properties in a DSS-treated rat model, and this was meditated by its pro-autophagic activity [35]. Another study using a new synthetic flavonoid, GL-V9, showed it protected against colitis-associated colorectal cancer via activation of autophagy [36]. Galangin is a known natural inducer for autophagy, in many cell types, including hepatocellular carcinoma (HCC) [37], colon cancer [38], and oesophageal carcinoma cells [39]. Although few reports have noted the effects of galangin on cellular autophagy during colitis, this current study has shown for the first time that galangin can restore the impaired autophagy in DSS-treated mice, which is a promising therapeutic target for the treatment of UC. However, this study only focused on the effects of autophagy induction by galangin in the colon, and further studies investigating the interactions between autophagy and other cell signaling pathways, such as inflammatory regulation of cell apoptosis, should be performed in the future.
It has been shown that the pathogenesis of IBD involves both genetic and environmental factors, and studies have also highlighted the important role of the intestinal microbiota. Dietary supplements with natural products, including flavonoids, have been shown to have a certain potential in maintaining and/or reshaping the gut microbiome [40]. Despite the fact that most flavonoids have poor absorption, the gut microbiome is still largely affected by flavonoids because they have a long dwell time in the gut. The modulating effects on the gut microbiome have been widely recognized as the major contributors to the beneficial effects of flavonoids. In a prior study, galangin was found to have prebiotic properties, on the basis of its ability to enhance the production of anti-inflammatory substances produced by Bifidobacterium adolescentis-a commensal bacteria often isolated from the human large intestine [41].
In parallel, this current study noted that galangin treatment increased the gut bacterial diversity in colitic mice and increased the relative abundance of several beneficial bacterial strains, including Mucispirillum spp., Bacteroides spp., and Anaerotruncus spp. [42]. These results are in line with previous findings from other groups that assessed the gastrointestinal protective effects of bee propolis and galangal [43]. SCFAs are known energy sources for gut microbes, as well as for colonic epithelial cells, both of which play key important roles in maintaining gut hemostasis. Similar to previous studies, this current study demonstrated that intestinal SCFAs were decreased following DSS treatment, and galangin treatment was able to reverse these changes by increasing the acetate and butyrate levels. It was also noted that galangin enriched some specific bacteria populations that were able to promote the production of SCFAs, such as Butyricimonas spp., which inferred that the protective effect of galangin against DSS-induced colitis was mechanistically related to its effects of increasing SCFA production mediated by its remodeling effects on the gut microbiota.
We acknowledged that our study has also some limitations. First, although a DSS-induced UC model was applied in this study, the real cause of human IBD is still elusive and cannot be really mimicked. Second, we only observed the acute colitic symptoms in the mice, and this time period of observation might be not enough to assess the potential clinical outcomes by galangin intervention.

Conclusions
Taken together, the results of this study have shown that the administration of galangin to mice was able to alleviate acute UC-like symptoms. As a natural dietary bioflavonoid, galangin demonstrated good anti-inflammatory effects by inhibiting inflammatory cytokines as well as inflammatory cell infiltrations. It was also noted that galangin restored the impaired autophagy in these colitic mice. Moreover, it was demonstrated that galangin could increase the diversity of the gut microbiota diversity and promote SCFA production. As a result, galangin has demonstrated great potential for use in the prevention of UC.